26 results on '"Selleslag, D."'
Search Results
2. Parvovirus B19-triggered hemophagocytic lymphohistiocytosis in a patient with Crohn's disease.
- Author
-
Debels, L., Reynders, M., Cauwelier, B., Willandt, B., Selleslag, D., and Snauwaert, C.
- Published
- 2022
- Full Text
- View/download PDF
3. P768: GUADECITABINE (SGI‐110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
- Author
-
Garcia‐Manero, G., Bart, S., McCloskey, J. K., Fenaux, P., Selleslag, D., Reda, G., Valcárcel, D., Santini, V., Mayer, J., Xicoy, B., Yamaguchi, H., Lübbert, M., Miyazaki, Y., Keer, H., Hao, Y., Azab, M., and Döhner, H.
- Published
- 2022
- Full Text
- View/download PDF
4. P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG‐TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML‐001 TRIAL OF ORAL AZACITIDINE.
- Author
-
Wei, A. H., Döhner, H., Sayar, H., Ravandi, F., Montesinos, P., Dombret, H., Selleslag, D., Porkka, K., Jang, J.‐H., Skikne, B., Beach, C., Prebet, T., Zhang, G., Risueño, A., Ugidos Guerrero, M., See, W. L., Menezes, D., and Roboz, G. J.
- Published
- 2022
- Full Text
- View/download PDF
5. P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B‐ALL IN ADULTS. A PHASE II HOVON TRIAL.
- Author
-
Rijneveld, A., Gradowska, P., Bellido, M., de Weerdt, O., Gadisseur, A., Deeren, D., van der Wagen, L., Jauw, Y., Fijnheer, R., van Lammerren, D., Selleslag, D., Halkes, S., Biemond, B., Breems, D., Moors, I., van Sluis, G., Bakkus, M., Homburg, C., Janda, V., and van der Velden, V.
- Published
- 2022
- Full Text
- View/download PDF
6. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
- Author
-
Meers, S., Selleslag, D., Potier, H., Glasmacher, A., Mineur, P., and Voelter, V.
- Subjects
AZACITIDINE ,MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,DISEASE complications ,THERAPEUTICS - Abstract
Objective: Azacitidine (Vidaza*) is approved in Europe for treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20–30% bone marrow (BM) blasts, and chronic myelomonocytic leukemia (CMML) with 10–29% BM blasts and no myeloproliferative syndrome (i.e.513.000/mL white blood cells). In Belgium, the azacitidine reimbursement process can take several months, and is often delayed at submission for medical assessment by the Belgian National Institute for Health and Disability Insurance of incomplete patient dossiers, due to disease complexity and classification, and administrative burden. We describe the Vidaza Access Program and its application to an initial 175 patients. Individual medical dossiers were reviewed for completeness to facilitate patient access to treatment in Belgium. Methods: A standardized anonymized patient information form is completed by the physician and sent for review to the Belgian Celgene Medical Department. The form is reviewed within three working days and, for complete dossiers, Celgene grants a financial guarantee for treatment with azacitidine. The patient can then be treated without the hospital being subjected to financial risk. Results: Between January 2013 and June 2014, 63 physicians (53 Belgian hospitals) recruited 175 patients. In total, 163 patient dossiers were approved by Celgene (120 MDS, 36 AML, and 7 CMML), of which 104 dossiers were also approved by the review committee and 49 have been waiting for a final decision for a median of 6 months; no information is currently available for the remaining 10. No dossiers approved by Celgene have been rejected by the review committee. Conclusions: The Celgene Vidaza Access Program offers support to healthcare professionals in the appropriate use of azacitidine. By facilitating the assessment of patient dossiers and providing a financial guarantee for prescribers and hospitals, treatment can be initiated more rapidly and patients may better benefit from azacitidine treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
- Author
-
Hübel, K, Fresen, M M, Apperley, J F, Basak, G W, Douglas, K W, Gabriel, I H, Geraldes, C, Jaksic, O, Koristek, Z, Kröger, N, Lanza, F, Lemoli, R M, Mikala, G, Selleslag, D, Worel, N, Mohty, M, and Duarte, R F
- Subjects
STEM cells ,CELL motility ,HODGKIN'S disease ,MULTIPLE myeloma ,GRANULOCYTE-macrophage colony-stimulating factor ,AUTOTRANSPLANTATION ,PATIENTS - Abstract
The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10
6 CD34+ cells/kg: 81.6%; >5.0 × 106 CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 106 CD34+ cells/kg: 64.8%; >5.0 × 106 CD34+ cells/kg: 12.6%; P<0.0001) and also significantly higher in HL patients (>2.0 × 106 CD34+ cells/kg: 81.5%; >5.0 × 106 CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
8. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.
- Author
-
Jacobs, F., Selleslag, D., Aoun, M., Sonet, A., and Gadisseur, A.
- Subjects
DRUG efficacy ,ASPERGILLOSIS treatment ,MYCOSES ,CLINICAL trials ,SCIENTIFIC observation ,DATA analysis - Abstract
The purpose of this study was to evaluate efficacy and safety of voriconazole in patients with acute invasive aspergillosis (IA) in a real-life, clinical setting. This was a multicenter observational study in adult patients treated with voriconazole for invasive mycosis. The study evaluated clinical response, mortality, use of other licensed antifungal therapy (OLAT), and treatment duration. This sub-analysis evaluated treatment and outcome data specifically from adult patients with proven/probable IA, while safety data were assessed in patients with proven/probable/possible IA. Of the 141 patients enrolled, 113 were adults with proven/probable IA and six had possible IA. Voriconazole treatment duration ranged from 1 to 183 days (median, 49.5 days). Voriconazole was used exclusively in 64% (72/113) of patients and in combination/sequentially with OLAT in 36%. Overall successful treatment response was 50% (57/113 patients). Twelve percent (14/113) of patients were switched to OLAT, either because of insufficient response (four patients) or for safety reasons (10 patients). Overall and attributable (entirely or partially due to fungal infection) mortality rates were 52% (59/113) and 17%, respectively. Treatment-related adverse events were reported for 18% (22/119) of patients. This observational study confirms the results of previous clinical trials demonstrating voriconazole as an effective and safe agent for treatment of confirmed acute IA. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient.
- Author
-
Andrei, G., Fiten, P., Goubau, P., van Landuyt, H., Gordts, B., Selleslag, D., De Clercq, E., Opdenakker, G., and Snoeck, R.
- Subjects
HERPES simplex virus ,HEMATOPOIETIC stem cells ,SKIN infections ,VIRUSES ,BLADDER diseases ,NEPHROTOXICOLOGY ,GENETIC polymorphisms ,ACYCLOVIR - Abstract
A hematopoietic stem cell transplant recipient developed a mucosal herpes simplex virus-1 (HSV-1) infection while under acyclovir (ACV) treatment (HSV was later shown to be resistant to ACV). Concomitantly, the patient presented a hemorrhagic cystitis (HC) due to polyomavirus BK, for which intravenous cidofovir (CDV) was prescribed. The patient benefited from the broad-spectrum anti-DNA virus activity of CDV, and not only the HC resolved without signs of nephrotoxicity but also the HSV-1 lesions disappeared. This is the first report describing the effect of CDV on 2 simultaneous and unrelated DNA viral infections in an immunosuppressed transplant recipient. In addition, we describe here that this HSV-1 isolate possesses a unique phenotype and genotype. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
10. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
- Author
-
Amadori, S., Suciu, S., Stasi, R., Willemze, R., Mandelli, F., Selleslag, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.-P., Beeldens, F., Baila, L., Vignetti, M., and de Witte, T.
- Subjects
MYELOID leukemia ,BONE marrow diseases ,FRAIL elderly ,DISEASES in older people ,ANTIBODY-toxin conjugates ,CD antigens - Abstract
The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were not considered eligible for conventional chemotherapy because of advanced age or poor performance status. The drug was administered at the dose of 9 mg/m2 as a single 2-h i.v. infusion on days 1 and 15. Patients who achieved a complete remission (CR/CRp) were to receive a consolidation with two additional injections of the immunotoxin at the same dose. The overall CR/CRp rate was 17% (95% CI, 8-32%). The CR/CRp rate in patients 61-75 years old was 33% (6/18), and 5% (1/22) in patients older than 75 years. Induction death occurred in seven patients (17%), all aged above 75 years. Overall survival was significantly longer in patients aged 61-75 years than in older individuals (P=0.05), and in CD33+ cases than in CD33- cases (P=0.05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
11. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.
- Author
-
Speleman, F., Cauwelier, B., Dastugue, N., Cools, J., Verhasselt, B., Poppe, B., van Roy, N., Vandesompele, J., Graux, C., Uyttebroeck, A., Boogaerts, M., de Moerloose, B., Benoit, Y., Selleslag, D., Billiet, J., Robert, A., Huguet, F., vandenberghe, P., de Paepe, A., and Marynen, P.
- Subjects
LYMPHOBLASTIC leukemia ,LYMPHOCYTIC leukemia ,CANCER genetics ,TUMOR suppressor genes ,GENETICS ,T cells - Abstract
Chromosomal translocations with breakpoints in T-cell receptor (TCR) genes are recurrent in T-cell malignancies. These translocations involve the TCRadgene (14q11), the TCRßgene (7q34) and to a lesser extent the TCR?gene at chromosomal band 7p14 and juxtapose T-cell oncogenes next to TCR regulatory sequences leading to deregulated expression of those oncogenes. Here, we describe a new recurrent chromosomal inversion of chromosome 7, inv(7)(p15q34), in a subset of patients with T-cell acute lymphoblastic leukemia characterized by CD2 negative and CD4 positive, CD8 negative blasts. This rearrangement juxtaposes the distal part of the HOXA gene cluster on 7p15 to the TCRßlocus on 7q34. Real time quantitative PCR analysis for all HOXA genes revealed high levels of HOXA10 and HOXA11 expression in all inv(7) positive cases. This is the first report of a recurrent chromosome rearrangement targeting the HOXA gene cluster in T-cell malignancies resulting in deregulated HOXA gene expression (particularly HOXA10 and HOXA11) and is in keeping with a previous report suggesting HOXA deregulation in MLL-rearranged T- and B cell lymphoblastic leukemia as the key factor in leukaemic transformation. Finally, our observation also supports the previous suggested role of HOXA10 and HOXA11 in normal thymocyte development.Leukemia (2005) 19, 358-366. doi:10.1038/sj.leu.2403657 Published online 27 January 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
12. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
- Author
-
Vandenberghe, P., Wlodarska, I., Michaux, L., Zachée, P., Boogaerts, M., Vanstraelen, D., Herregods, M-C, van Hoof, A., SelIeslag, D., Roufosse, F., Maerevoet, M., Verhoef, G., Cools, J., Gilliland, DG, Hagemeijer, A., Marynen, P., Zachée, P, Selleslag, D, and Gilliland, D G
- Subjects
LEUKEMIA ,EOSINOPHIL disorders ,EOSINOPHILIA ,IMATINIB ,ANTINEOPLASTIC agents ,EOSINOPHILS ,DIAGNOSIS ,IN situ hybridization ,DIAGNOSTIC use of fluorescence in situ hybridization ,PROTEIN analysis ,HETEROCYCLIC compounds ,RNA analysis ,BENZAMIDE ,CELL receptors ,CELLS ,CHROMOSOMES ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,POLYMERASE chain reaction ,PROTEINS ,RESEARCH ,SURVIVAL ,PHENOTYPES ,FLUORESCENCE in situ hybridization ,EVALUATION research ,RETROSPECTIVE studies ,REVERSE transcriptase polymerase chain reaction ,DISEASE complications ,HYPEREOSINOPHILIC syndrome - Abstract
Detection of the FIP1L1-PDGFRA fusion gene or the corresponding cryptic 4q12 deletion supports the diagnosis of chronic eosinophilic leukemia (CEL) in patients with chronic hypereosinophilia. We retrospectively characterized 17 patients fulfilling WHO criteria for idiopathic hypereosinophilic syndrome (IHES) or CEL, using nested RT-PCR and interphase fluorescence in situ hybridization (FISH). Eight had FIP1L1-PDGFRA (+) CEL, three had FIP1L1-PDGFRA (-) CEL and six had IHES. FIP1L1-PDGFRA (+) CEL responded poorly to steroids, hydroxyurea or interferon-alpha, and had a high probability of eosinophilic endomyocarditis (n=4) and disease-related death (n=4). In FIP1L1-PDGFRA (+) CEL, palpable splenomegaly was present in 5/8 cases, serum vitamin B(12) was always markedly increased, and marrow biopsies revealed a distinctively myeloproliferative aspect. Imatinib induced rapid complete hematological responses in 4/4 treated FIP1L1-PDGFRA (+) cases, including one female, and complete molecular remission in 2/3 evaluable cases. In the female patient, 1 log reduction of FIP1L1-PDGFRA copy number was reached as by real-time quantitative PCR (RQ-PCR). Thus, correlating IHES/CEL genotype with phenotype, FIP1L1-PDGFRA (+) CEL emerges as a homogeneous clinicobiological entity, where imatinib can induce molecular remission. While RT-PCR and interphase FISH are equally valid diagnostic tools, the role of marrow biopsy in diagnosis and of RQ-PCR in disease and therapy monitoring needs further evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
13. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK...
- Author
-
Oosterveld, M, Suciu, S, Verhoef, G, Labar, B, Belhabri, A, Aul, C, Selleslag, D, Ferrant, A, Wijermans, P, Mandelli, F, Amadori, S, Jehn, U, Muus, P, Zittoun, R, Hess, U, Anak, O, Beeldens, F, Willemze, R, and de Witte, T
- Subjects
MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,DRUG therapy ,STEM cell transplantation - Abstract
This report used the framework of a large European study to investigate the outcome of patients with and without an HLA-identical sibling donor on an intention-to-treat basis. After a common remission-induction and consolidation course, patients with an HLA-identical sibling donor were scheduled for allogeneic transplantation and patients lacking a donor for autologous transplantation. In all, 159 patients alive at 8 weeks from the start of treatment were included in the present analysis. In total, 52 patients had a donor, 65 patients did not have a donor and in 42 patients the availability of a donor was not assessed. Out of 52 patients, 36 (69%) with a donor underwent allogeneic transplantation (28 in CR1). Out of 65 patients, 33 (49%) received an autograft (27 in CR1). The actuarial survival rates at 4 years were 33.3% (s.e. = 6.7%) for patients with a donor and 39.0% (s.e. = 6.5%) for patients without a donor (P = 0.18). Event-free survival rates were 23.1% (s.e. = 6.2%) and 21.5% (s.e. = 5.3%), respectively (P = 0.66). Correction for alternative donor transplants did not substantially alter the survival of the group without a donor. Also, the survival in the various cytogenetic risk groups was not significantly different when comparing the donor vs the no-donor group. This analysis shows that patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia may benefit from both allogeneic and autologous transplantation. We were unable to demonstrate a survival advantage for patients with a donor compared to patients without a donor. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
14. Donor lymphocyte infusions in adult haploidentical transplant:a dose .nding study.
- Author
-
Lewalle, P., Triffet, A., Delforge, A., Crombez, P., Selleslag, D., De Muynck, H., Bron, D., and Martiat, P.
- Subjects
TRANSPLANTATION of organs, tissues, etc. ,LYMPHOCYTES - Abstract
Haploidentical transplantation has become a clinical option for patients lacking a compatible donor. However, patients are still referred at advanced stages and are usually heavily pretreated. This results in a high risk of toxicity, relapses and infections. We therefore started a donor lymphocyte infusion (DLI) dose-finding protocol, to try to improve both relapse rate and immunity reconstitution. In all, 12 consecutive patients were investigated. Ail had a refractory, some progressive, disease. Conditioning consisted of TBI, melphalan, ATG, fludarabine and CSA pretransplant. In four rapidly progressive patients, Ara-C had to be given 1 week preconditioning. The graft was T- and B-cell depleted with a fixed reinfused CD3 dose of 5 x 104/kg. All patients engrafted before day 20. G-CSF was given from day 5 post-transplant and replaced with GM-CSF in the last three patients. Nonrelapse related mortality was 0/12 at I year. DLI were started at day 28 (3 X 104 CD3/kg) in the two first patients. This resulted in acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) in both, but they did not relapse. The next dose was 1 x 104/kg monthly for 3 months. This was well tolerated with only one grade I GVHD. Given the high relapse rate, we escalated doses (1, 3 and 10 x 104/kg). This produced GVHD in all. We next moved, to GM-CSF and 1 x 104 CD3/kg monthly. Overall, 6/12 patients relapsed and received therapeutic DLI, starting at 1 x 105 CD3/kg with escalation every 2 weeks. We conclude that prophylactic DLI are feasible in adult haploidentical transplantation, without GVHD at a monthly dose of 1 x 104 CD3/kg. They result in faster CD4 recovery and a low rate of infections. The impact of GM-CSF remains to be further investigated. This scheme seems ideal for patients... [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
15. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.
- Author
-
Oosterveld, M., Muus, P., Suciu, S., Koller, C., Verhoef, G., Labar, B., Wijermans, P., Aul, C., Fiere, D., Selleslag, D., Willemze, R., Gratwohl, A., Ferrant, A., Mandelli, F., Cortes, J., de Witte, T., and Estey, E.
- Subjects
LEUKEMIA treatment ,DRUG therapy ,STEM cells ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Comparisons of the effectiveness of chemotherapy and transplantation in AML in first complete remission (CR) have focused almost exclusively on patients with de novo disease. Here we used Cox modelling to compare these strategies in patients with MDS and s-AML treated by the Leukemia Group of the EORTC or at the MD Anderson Cancer Center. All patients were aged 15-60. The 184 EORTC patients received conventional dose ara-C + idarubicin + etoposide for remission induction, and after one consolidation course, were scheduled to receive an allograft, or an autograft if a sibling donor was unavailable. The 215 MDA patients received various high-dose ara-C containing induction regimens, and in CR, continued to receive these regimens at reduced dose for 6-12 months. CR rates were 54% EORTC and 63% MDA (P = 0.09). Sixty-five of the 100 EORTC patients who entered CR received a transplant in first CR. Disease-free survival in patients achieving CR was superior in the EORTC cohort, the 4-years DFS rates were 28.9% (s.e. = 4.8%) EORTC vs 17.3% (s.e. = 3.7%) MDA (P = 0.017). Survival from CR was not significantly different in the EORTC and MDA groups, as was survival from start of treatment. After accounting for prognostic factors the conclusions were unchanged. Despite various problems with the analysis discussed below, the data suggest that neither transplantation nor chemotherapy, as currently practised, can be unequivocally recommended for these patients in first CR and that questions as to the superior modality may be less important than the need to improve results with both. [ABSTRACT FROM AUTHOR]
- Published
- 2002
16. Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus.
- Author
-
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., BIlle, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J. F., Patterson, T. F., Ritter, J., Selleslag, D., Shah, P. M., and Stevens, D. A.
- Subjects
MYCOSES ,OPPORTUNISTIC infections ,CANCER patients ,HEMATOPOIETIC stem cell transplantation - Abstract
During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for IFIs for clinical research. On the basis of a review of literature and an international consensus, a set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed. Three levels of probability are proposed: 'proven,' 'probable,' and 'possible.' The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2002
17. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing.
- Author
-
Nollet, F, Billiet, J, Selleslag, D, and Criel, A
- Subjects
FOURIER transform spectroscopy ,TRANSPLANTATION of organs, tissues, etc. ,HEMATOPOIETIC stem cells - Abstract
To evaluate the origin of cells after allogeneic haematopoietic stem cell transplantation we optimised and evaluated two commercially available systems (AmpFlSTR Profiler Plus and GenePrint Powerplex-16) which are based on multiplex fluorescent short tandem repeat (STR) analysis. A standard procedure for interpretation of electropherographs was found essential to obtain reproducible results. On the basis of the relative length of donor and recipient alleles, TYPE-I (no shared alleles are used to calculate chimerism), TYPE-II (one shared and one unshared allele is used to calculate chimerism) or TYPE-III (not informative) allelic distribution types were distinguished. Also, stutter peaks were recognised as an important criterion to exclude a marker for analysis. Intralaboratory and multicentre evaluation of the AmpFlSTR Profiler Plus system showed that mixed blood samples could be determined with an absolute deviation of less than 2%. A sensitivity threshold was set at 5% for TYPE-I and 10% for TYPE-II markers since relative imprecision increases at low chimerism values. No significant difference of calculated chimerism values was observed between STR markers shared between both systems. By monitoring 26 allogeneic peripheral blood stem cell transplants, the applicability of the proposed method was demonstrated. Bone Marrow Transplantation (2001) 28, 511–518. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
18. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma.
- Author
-
Cuneo, A, Bardi, A, Wlodarska, I, Selleslag, D, Roberti, M G, Bigoni, R, Cavazzini, F, De Angeli, C, Tammiso, E, del Senno, L, Cavazzini, P, Hagemeijer, A, and Castoldi, G
- Subjects
CHROMOSOMAL translocation ,B cell lymphoma - Abstract
A novel recurrent translocation t(11;14)(p11;q32) was found in three patients with splenic marginal zone B cell lymphoma (MZBCL). Fluorescence in situ hybridization (FISH) studies with IgH probes revealed in all cases involvement of the IgH locus, with breakpoint downstream of the IGVH sequences. Partner genes at 11p11 were not identified. The translocation defined the stem line in two patients, who carried additional cytogenetic aberrations, including a 17p deletion, present in both cases. In one patient a 7q- chromosome was the primary cytogenetic defect, the t(11;14) having been found in four out of 11 abnormal metaphase cells at the time of transformation into high-grade MZBCL. Hematological features in all cases included splenomegaly with peripheral blood (PB) involvement by a monoclonal B cell population consisting of lymphocytes with villous projections and several blast-like cells. The immunophenotype was CD19+; CD22bright+; CD23-, CD10-, CD5-, surface Igbright+. A bone biopsy in one patient revealed an interstitial infiltration with an intrasinusoidal pattern of growth. Histological studies on spleen specimens in two patients showed an expanded marginal zone, with small lymphocytes and several blast-like cells. One patient had a therapy-demanding disease, with partial, short-term responses to cytotoxic treatment; one patient transformed into a high-grade MZBCL involving the gut, the PB and the bone marrow 2 years after diagnosis; one patient was unresponsive to cytotoxic treatment and underwent splenectomy. The t(11;14)(p11;q32) may define a subset of splenic MZBCL with a high-grade component and a relatively aggressive clinical behavior. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
19. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients.
- Author
-
Boogaerts, Marc, Maertens, Johan, van Hoof, Achiel, de Bock, Robrecht, Fillet, Georges, Peetermans, Marc, Selleslag, Dominik, Vandercam, Bernard, Vandewoude, Koenraad, Zachée, Pierre, De Beule, Karel, Boogaerts, M, Maertens, J, van Hoof, A, de Bock, R, Fillet, G, Peetermans, M, Selleslag, D, Vandercam, B, and Vandewoude, K
- Abstract
The efficacy and safety of itraconazole oral solution and a combination of amphotericin B capsules plus nystatin oral suspension were compared in the prophylaxis of fungal infections in neutropenic patients. In an open, randomized, multicentre trial, 144 patients received itraconazole oral solution 100 mg bd, and 133 patients received amphotericin B 500 mg tds plus nystatin 2 MU qds. Overall, 65% of itraconazole-treated patients were considered to have had successful prophylaxis, compared with 53% in the polyene group. Proven deep fungal infections occurred in 5% of patients in each group. Fewer patients receiving itraconazole than amphotericin plus nystatin had superficial infections (3 versus 8%; P = 0.066). This trend in favour of itraconazole was seen in patients with profound neutropenia (neutrophil count <0.1 x 10(9) cells/L at least once) or prolonged neutropenia (neutrophil count <1.0 x 10(9) cells/L for >14 days). The median time to prophylactic failure was longer in the itraconazole group (37 days) than in the polyene group (34 days). The number of patients with fungal colonization (nose, sputum, stool) changed more favourably from baseline to endpoint in the itraconazole group than in the polyene group. Both treatments were safe and well tolerated; however, patients receiving amphotericin plus nystatin had a higher incidence of nausea and rash. In conclusion, itraconazole oral solution at doses of 100 mg bd and oral amphotericin B plus nystatin have similar prophylactic efficacy against fungal infections in neutropenic patients. On the basis of reduced incidence of superficial fungal infections, fungal colonization and specific adverse events, itraconazole may be the preferred treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
20. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
- Author
-
Hale, G, Jacobs, P, Wood, L, Fibbe, W E, Barge, R, Novitzky, N, Toit, C du, Abrahams, L, Thomas, V, Bunjes, D, Duncker, C, Wiesneth, M, Selleslag, D, Hidajat, M, Starobinski, M, Bird, P, and Waldmann, H
- Subjects
IMMUNOGLOBULINS ,GRAFT rejection ,TRANSPLANTATION immunology ,HOMOGRAFTS - Abstract
Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T cell depletion increases the risk of graft rejection. In this study, two strategies are used to overcome rejection: (1) use of high doses of stem cells obtained from peripheral blood (PBSC), (2) admixture with a CD52 monoclonal antibody in order to deplete both donor and residual recipient lymphocytes. Two antibodies are compared: CAMPATH-1G (rat IgG2b) and its humanized equivalent CAMPATH-1H (human IgG1). A total of 187 consecutive patients at six centers received PBSC transplants from HLA-matched siblings between 1997 and 1999. A wide spectrum of diseases, both malignant and non-malignant, was included. The recovery of CD34
+ cells after antibody treatment was close to 100%. The risk of acute GVHD (grade 2 to 4) was 11% in the CAMPATH-1G group and 4% in the CAMPATH-1H group (P = NS). The risk of chronic GVHD (any grade) was 11% in the CAMPATH-1G group and 24% in the CAMPATH-1H group (P = 0.03) but the risk of extensive chronic GVHD was only 2%. The overall risk of graft failure/rejection was 2%, not significantly different between the two antibodies. Antibody treatment was equally effective at concentrations between 10 μg/ml and 120 μg/ml and it made no significant difference to the outcome whether the patients received post-transplant immunosuppression or not (87% did not). Transplant-related mortality in this heterogenous group of patients (including high-risk and advanced disease) was 22% at 12 months. It is proposed that treatment of peripheral blood stem cells with CAMPATH-1H is a simple and effective method for depleting T cells which may be applicable to both autologous and allogeneic transplants from related or unrelated donors. Special advantages of this approach are the simultaneous depletion of donor B cells (which reduces... [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
21. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
- Author
-
Verhoef, G., Zachée, P., Ferrant, A., Demuynck, H., Selleslag, D., Hove, L., Deckers, F., Boogaerts, M., Verhoef, G E, Zachée, P, Van Hove, L, and Boogaerts, M A
- Subjects
ERYTHROPOIETIN ,GRANULOCYTES ,IRON metabolism ,RECOMBINANT proteins ,ANEMIA ,BONE marrow ,CELLULAR aging ,GENETICS ,HEMATOPOIESIS ,MYELODYSPLASTIC syndromes ,DISEASE complications ,PHYSIOLOGY ,THERAPEUTICS - Abstract
The clinical and ferrokinetic effects of escalating doses of subcutaneously administered recombinant human erythropoietin (rh-EPO) were studied in ten patients with myelodysplastic syndromes and severe transfusion-dependent anemia. Red blood cell transfusion requirements diminished in four patients, and one of the patients eventually became transfusion independent with an EPO-induced rise of Hb from 7.7 g/dl to 12.3 g/dl. Endogenous serum levels of EPO were significantly increased in all patients (100-5700 mU/ml), but three of four responders had a relatively low baseline level. The effective red cell iron turnover (RCIT) improved in two responding patients and even normalized in one patient. This increase in RCIT was accompanied with a decline in the ineffective red cell iron turnover (IIT). The other responding patients had a relatively preserved RCIT before EPO treatment. EPO therapy further increased the fraction of IIT in the latter patients. Red cell survival time did not increase during EPO therapy, even in the responding patients. One transient and one maintained increase in platelet count were observed. Disease progression with a sustained increase in blast cells in one patient and a transient elevation of blasts in another patient was seen. No other side effects of EPO therapy were observed. These results suggest that anemic MDS patients with low serum EPO levels and relatively spared effective erythropoiesis as measured by ferrokinetic studies may be the best candidates for treatment with recombinant human EPO. [ABSTRACT FROM AUTHOR]
- Published
- 1992
- Full Text
- View/download PDF
22. An EORTC International Multicenter Randomized Trial (EORTC Number 19923) Comparing Two Dosages of Liposomal Amphotericin B for Treatment of Invasive Aspergillosis.
- Author
-
Ellis, M., Spence, D., Pauw, B. de, Meunier, F., Marinus, A., Collette, L., Sylvester, R., Meis, J., Boogaerts, M., Selleslag, D., Krcmery, V., von Sinner, W., MacDonald, P., Doyen, C., and Vandercam, B.
- Abstract
This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis (IA) and the first to compare the clinical efficacy of two dosages of liposomal amphotericin B (L-AmB) for IA in neutropenic patients with cancer or those undergoing bone marrow transplantation. Eighty-seven of 120 patients were eligible and evaluable. Clinical responses were documented for 26 (64%) of 41 patients receiving 1 mg/(kg · d) (L-AmB-1) and 22 (48%) of 46 receiving 4 mg/(kg · d) (L-AmB-4). Radiologic response rates were similar: 24 (58%) of the L-AmB-1 recipients and 24 (52%) of the L-AmB-4 recipients. The six-month survival rates were 43% (L-AmB-1) and 37% (L-AmB-4). These differences were not significant. The numbers of deaths directly due to IA at 6 months were similar: 9 (22%) of 41 L-AmB-1 recipients and 9 (20%) of 46 L-AmB-4 recipients. No other variable independently influenced survival, apart from central nervous system IA. L-AmB is effective in treating ∼50%–60% of patients who have IA. A 1-mg/(kg · d) dosage is as effective as a 4-mg/(kg · d) dosage, and no advantages to use of the higher, more expensive, dosage has been observed. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
23. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
- Author
-
De Witte, T, Suciu, S, Selleslag, D, Labar, B, Roozendaal, K, Zittoun, R, Ribeiro, M, Kurstjens, R, Hayat, M, Dardenne, M, Solbu, G, and Muus, P
- Abstract
Twenty-one patients with acute myeloid leukemia (AML) who failed to enter complete remission (CR) after first-line standard-dose remission-induction therapy with 7 days of cytarabine and 3 days of daunorubicin were treated with a salvage regimen containing intermediate-dose cytosine arabinoside (Ara-C) 2 x 500 mg/m2/day during 7 days in combination with continuous infusions of idarubicin 12 mg/m2/day on days 1, 3, and 5. Twenty patients were considered primary resistant, and one patient had a partial remission after two remission-induction courses. Overall, 11 patients (52%, 95% confidence interval: 30-74%) entered CR. Three patients died during hypoplasia and seven patients had resistant disease or a partial remission. The remission rate in this study compares favorably with the results obtained in similar patient categories. The toxicity of this salvage regimen was remarkably mild. No extramedullary toxicity was observed except for hepatic dysfunction in seven patients. The median duration of remission was 8.5 months, and ultimately, all complete remitters have relapsed except the patient who died from infectious complications after allogeneic bone marrow transplantation (BMT). This study shows that new intensive chemotherapy regimens may be effective after failure of primary treatment. Salvage regimens containing intermediate/high-dose Ara-C and/or alternative anthracyclines or anthracenes should be induced in the treatment of young patients with de novo AML. [ABSTRACT FROM AUTHOR]
- Published
- 1996
24. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
- Author
-
Witte, T. De, Suciu, S., Selleslag, D., Labar, B., Roozendaal, K., Zittoun, R., Ribeiro, M., Kurstjens, R., Hayat, M., Dardenne, M., Solbu, G., and Muus, P.
- Abstract
Twenty-one patients with acute myeloid leukemia (AML) who failed to enter complete remission (CR) after first-line standard-dose remission-induction therapy with 7 days of cytarabine and 3 days of daunorubicin were treated with a salvage regimen containing intermediate-dose cytosine arabinoside (Ara-C) 2×500 mg/m/day during 7 days in combination with continuous infusions of idarubicin 12 mg/m/day on days 1, 3, and 5. Twenty patients were considered primary resistant, and one patient had a partial remission after two remission-induction courses. Overall, 11 patients (52%, 95% confidence interval: 30-74%) entered CR. Three patients died during hypoplasia and seven patients had resistant disease or a partial remission. The remission rate in this study compares favorably with the results obtained in similar patient categories. The toxicity of this salvage regimen was remarkably mild. No extramedullary toxicity was observed except for hepatic dysfunction in seven patients. The median duration of remission was 8.5 months, and ultimately, all complete remitters have relapsed except the patient who died from infectious complications after allogeneic bone marrow transplantation (BMT). This study shows that new intensive chemotherapy regimens may be effective after failure of primary treatment. Salvage regimens containing intermediate/high-dose Ara-C and/or alternative anthracyclines or anthracenes should be induced in the treatment of young patients with de novo AML. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
25. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.
- Author
-
Basak, G W, Wiktor-Jedrzejczak, W, Apperley, J F, Douglas, K W, Gabriel, I H, Geraldes, C, Hübel, K, Jaksic, O, Koristek, Z, Lanza, F, Lemoli, R, Mikala, G, Selleslag, D, Worel, N, Mohty, M, and Duarte, R F
- Subjects
LETTERS to the editor ,BODY mass index ,STEM cells - Abstract
A letter to the editor is presented which discusses the possible correlation of higher body mass index (BMI) to stem cell mobilization with standard doses of granulocytecolony stimulating factor (G-CSF) and plerixafor.
- Published
- 2012
- Full Text
- View/download PDF
26. Acute thyrotoxicosis after SCT.
- Author
-
De Waele, S., Van den Bruel, A., Selleslag, D., Van Den Berghe, I., and Decallonne, B.
- Subjects
LETTERS to the editor ,DRUG side effects ,DISEASE prevalence - Abstract
A letter to the editor is presented in response to the article about the prevalence of thyrotoxicosis after SCT in the previous issue.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.